Silvia Muro

5.9k total citations
100 papers, 4.8k citations indexed

About

Silvia Muro is a scholar working on Molecular Biology, Biomaterials and Physiology. According to data from OpenAlex, Silvia Muro has authored 100 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Molecular Biology, 32 papers in Biomaterials and 27 papers in Physiology. Recurrent topics in Silvia Muro's work include Nanoparticle-Based Drug Delivery (32 papers), Lysosomal Storage Disorders Research (22 papers) and Cell Adhesion Molecules Research (19 papers). Silvia Muro is often cited by papers focused on Nanoparticle-Based Drug Delivery (32 papers), Lysosomal Storage Disorders Research (22 papers) and Cell Adhesion Molecules Research (19 papers). Silvia Muro collaborates with scholars based in United States, Spain and Nepal. Silvia Muro's co-authors include Vladimir R. Muzykantov, Carmen Garnacho, Michael Koval, Edward H. Schuchman, Christine Gajewski, John Leferovich, Tridib Kumar Bhowmick, Melani Solomon, Steven Μ. Albelda and Xiumin Cui and has published in prestigious journals such as Blood, ACS Nano and Nature Biotechnology.

In The Last Decade

Silvia Muro

99 papers receiving 4.8k citations

Peers

Countries citing papers authored by Silvia Muro

Since Specialization

Citations

This map shows the geographic impact of Silvia Muro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Muro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Muro more than expected).

Fields of papers citing papers by Silvia Muro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Muro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Muro. The network helps show where Silvia Muro may publish in the future.

Co-authorship network of co-authors of Silvia Muro

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Muro. A scholar is included among the top collaborators of Silvia Muro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Muro. Silvia Muro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ICAM-1 targeting of nanocarriers in a human blood-brain-barrier-on-a-chip complements in vivo brain delivery observations 2025 ·Journal of drug targeting ·(unknown), (unknown), (unknown), (unknown), (unknown), Marina I. Giannotti, Anna Lagunas, Mònica Mir, Josep Samitier, Silvia Muro	0
2	New cellular models to support preclinical studies on ICAM-1-targeted drug delivery 2024 ·Journal of Drug Delivery Science and Technology ·(unknown), (unknown), (unknown), (unknown), (unknown), Silvia Muro	2
3	Role of the Lactide:Glycolide Ratio in PLGA Nanoparticle Stability and Release under Lysosomal Conditions for Enzyme Replacement Therapy of Lysosomal Storage Disorders 2023 ·Journal of Functional Biomaterials ·(unknown), (unknown), (unknown), (unknown), Vy Pham, Peter Pfeifer, Giuseppe Battaglia, Silvia Muro	4
4	Comparison between Nanoparticle Encapsulation and Surface Loading for Lysosomal Enzyme Replacement Therapy 2022 ·International Journal of Molecular Sciences ·(unknown), Marcelle Silva-Abreu, (unknown), (unknown), Vy Pham, (unknown), Melani Solomon, Silvia Muro	15
5	Tuning Design Parameters of ICAM-1-Targeted 3DNA Nanocarriers to Optimize Pulmonary Targeting Depending on Drug Type 2022 ·Pharmaceutics ·(unknown), Melani Solomon, Jessica Bowers, Lori Getts, Robert Getts, Silvia Muro	4
6	A method to improve quantitative radiotracing‐based analysis of the in vivo biodistribution of drug carriers 2020 ·Bioengineering & Translational Medicine ·(unknown), Melani Solomon, (unknown), Jessica Bowers, Robert Getts, Silvia Muro	5
7	Intertwined mechanisms define transport of anti-ICAM nanocarriers across the endothelium and brain delivery of a therapeutic enzyme 2020 ·Journal of Controlled Release ·Rachel L. Manthe, (unknown), Tridib Kumar Bhowmick, Melani Solomon, Silvia Muro	20
8	Unprecedently high targeting specificity toward lung ICAM-1 using 3DNA nanocarriers 2019 ·Journal of Controlled Release ·(unknown), (unknown), Melani Solomon, Jessica Bowers, Robert Getts, Silvia Muro	23
9	Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain 2019 ·Journal of Controlled Release ·Oscar A. Marcos‐Contreras, (unknown), Raisa Y. Kiseleva, Viviana Zuluaga‐Ramirez, Colin F. Greineder, Carlos H. Villa, Elizabeth D. Hood, Jacob W. Myerson, Silvia Muro, Yuri Persidsky, Vladimir R. Muzykantov	46
10	Alterations in Cellular Processes Involving Vesicular Trafficking and Implications in Drug Delivery 2018 ·Biomimetics ·Silvia Muro	25
11	Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance 2017 ·Biomaterials ·Joshua Kim, Sauradeep Sinha, Melani Solomon, Edgar Pérez‐Herrero, Janet Hsu, (unknown), Silvia Muro	30
12	A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders 2015 ·Molecular Pharmaceutics ·Jeffrey A. Rappaport, Rachel L. Manthe, Melani Solomon, Carmen Garnacho, Silvia Muro	30
13	Targeting, Endocytosis, and Lysosomal Delivery of Active Enzymes to Model Human Neurons by ICAM-1-Targeted Nanocarriers 2014 ·Pharmaceutical Research ·Janet Hsu, Janet Hoenicka, Silvia Muro	17
14	Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease 2010 ·Journal of Controlled Release ·Janet Hsu, Daniel Serrano, Tridib Kumar Bhowmick, (unknown), (unknown), (unknown), Carmen Garnacho, Silvia Muro	70
15	Oxygen Microscopy by Two‐Photon‐Excited Phosphorescence 2008 ·ChemPhysChem ·Olga S. Finikova, Artem Y. Lebedev, Alexey Aprelev, Thomas Troxler, Feng Gao, Carmen Garnacho, Silvia Muro, Robin M. Hochstrasser, Sergei A. Vinogradov	187
16	Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis 2005 ·Molecular Therapy ·Silvia Muro, Edward H. Schuchman, Vladimir R. Muzykantov	102
17	Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na⁺/H⁺exchanger proteins 2005 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Silvia Muro, (unknown), Christine Gajewski, (unknown), Vladimir R. Muzykantov, Michael Koval	59
18	Effect of PCCB Gene Mutations on the Heteromeric and Homomeric Assembly of Propionyl-CoA Carboxylase 2001 ·Molecular Genetics and Metabolism ·Silvia Muro, Belén Pérez, Lourdes R. Desviat, Pilar Rodríguez‐Pombo, Celia Pérez‐Cerdá, Sonia Clavero, Magdalena Ugarte	18
19	Identification of novel mutations in the PCCB gene in European propionic acidemia patients 1999 ·Human Mutation ·Silvia Muro, Pilar Rodríguez‐Pombo, (unknown), (unknown), Lourdes R. Desviat, Wolfgang Sperl, Daniela Skladal, Jörn Oliver Sass, Magdalena Ugarte	18
20	Overview of mutations in thePCCA andPCCB genes causing propionic acidemia 1999 ·Human Mutation ·Magdalena Ugarte, (unknown), Pilar Rodríguez‐Pombo, Lourdes R. Desviat, (unknown), Eva Richard, Silvia Muro, Eric Campeau, Toshihiro Ohura, Roy A. Gravel	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact